GE HealthCare (GEHC) · Deep analysis

Report previewGEHC.USReport date Last updated
← Back to reports
Report contents

At a glance

  • Business model: GE HealthCare sells imaging, ultrasound and patient-monitoring equipment to hospitals, then earns service and consumables revenue on the installed base; Pharmaceutical Diagnostics contrast media and tracers are consumed per scan. FY2025 revenue of $20.62 billion carried a 40.0% gross margin. The obstacle is that service revenue and renewal rates are not reported separately, so the recurring pool is inferred from segment trends.
  • Financial quality: Free cash flow was positive in each of the last five fiscal years, but conversion to net income ran below 0.8 in three of them, and the June 2026 quarter produced a $0.62 billion outflow. Net debt near $7.1 billion is about 1.9 times FY2025 EBITDA of $3.79 billion; interest is covered roughly seven times and $3.5 billion of undrawn revolvers sit behind it.
01

Business model

Business model: the installed base pays the bills

GE HealthCare sells hospitals the equipment they use to look inside patients, then keeps selling to them for years afterward. The catalog runs from CT, MRI, X-ray and molecular imaging scanners to ultrasound systems, patient monitoring and anesthesia machines, plus pharmaceutical diagnostics: contrast media injected before a scan and tracers used in molecular imaging. Buyers are hospitals, integrated delivery networks, imaging centers, ambulatory and physician practices, and public health systems, concentrated in North America, Europe and China with additional scale in Japan and India. That makes it a regulated capital-equipment manufacturer with a recurring service and consumables tail, three years past its spin-off from General Electric and now managed for organic growth and margin.

Capital sales open the account; service and tracers keep it

The profit pool does not sit in the first scanner. GE HealthCare reported about $19.7 billion of revenue in FY2024 across four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics, the smallest of the four. Service revenue sits inside the equipment segments instead of a separate reporting line, so the size, growth and margin of the recurring pool are not directly disclosed. It has to be read from segment trends, procedure volumes and the company's commentary on its installed base. That gap shapes interpretation: a weak order quarter and a weakening franchise are different events, and only segment detail starts to separate them.

A scanner sold today produces modest revenue up front and a decade of parts, service, upgrades, software and consumable sales afterward. Pharmaceutical Diagnostics runs on a different clock. Contrast media and tracers are consumed each time a patient is scanned, so that revenue tracks utilization more than installations and responds to procedure growth instead of hospital capital budgets. GE HealthCare's earnings are therefore less cyclical than a pure equipment supplier's. Consumables also carry regulated manufacturing obligations and meet the same concentrated buyers, so volume growth does not guarantee margin growth.

Hospital buyers hold most of the pricing power

Hospitals and integrated delivery networks rarely negotiate one machine at a time. They buy across sites, often through group purchasing organizations (alliances that aggregate member volume into a single negotiated price), and public systems run formal tenders. Concentrated buyers push standardized modalities toward cost, which moves competition to uptime, service response, image quality and clinical results. GE HealthCare's opening advantage is breadth: it can equip radiology, cardiology, oncology, surgery and acute care, then hold the service relationship across all of them. Rivals for the same radiology budgets include Siemens Healthineers, Philips, Canon Medical and, increasingly in China, United Imaging, so breath of portfolio is the differentiator the company leans on.

Breadth wins access; it does not guarantee price. When a deal is won with a discount, revenue rises and the working capital behind it rises too, while earnings stay closer to flat. Growth therefore depends more on mix and volume than on headline list prices, and a pricing gain should appear in segment margin before it appears in orders.

Replacement cycles make share move slowly, in both directions

Imaging hardware is replaced on a long cycle, typically measured in years rather than quarters. Once a system is installed and a service contract is signed, the customer is largely committed for the life of the equipment, and competitors have to wait for the next refresh or for an unmet clinical need to unseat it. The same inertia works against GE HealthCare: an account lost to a rival is not recovered quickly, and disappointing products can weigh on a geography or modality for years. This is an inference from how the industry sells, not a disclosed figure, but it explains why order intake shifts gradually and why a single tender loss should not be read as a change in competitive position.

China and the capital-budget cycle set the pace

Order timing follows hospital budgets, reimbursement decisions and government procurement programs, which makes any quarter's growth a poor guide to the franchise. China carries the most policy sensitivity of the major markets: local-content preferences and hospital equipment programs can pull orders forward or defer them for several quarters. If the China mix shifts toward locally manufactured systems, revenue can hold while average selling prices fall, and the same volume contributes less profit. Public health systems elsewhere add their own tender calendars, so reported growth will stay lumpy even when underlying demand is steady.

What would change the read

The judgment here is that the installed base and the recurring tail carry the economics, while equipment orders mainly set the timing. Three observations would overturn it: Pharmaceutical Diagnostics growth falling behind procedure volumes, Imaging and Ultrasound growth achieved largely through price concessions, or a reporting change showing service revenue is smaller or less sticky than the current framing implies. Service attach and renewal rates are not broken out, so the recurring-revenue case rests on inference from segment trends and utilization. Until that disclosure improves, the question stays open.

Questions worth following

  • Do hospitals keep buying GE HealthCare service and diagnostics after installation?

    Recurring service, software and contrast media revenue is what separates a durable franchise from a cyclical equipment seller. If hospitals renew service contracts and scan volumes rise, earnings are steadier and less dependent on hospital capital budgets; if the tail is thin, revenue swings with tender timing.

  • Can GE HealthCare defend imaging prices as hospital buyers consolidate?

    Group purchasing organizations and public tenders set price for most imaging deals. If GE HealthCare holds price while winning volume, mix and margins improve and the installed base compounds; if it buys share with discounts, revenue grows while returns on the same capital base do not.

  • Will China hospital equipment demand lift GE HealthCare's order growth?

    China is one of the company's largest markets, and its order timing moves with procurement policy and local-content rules. A durable recovery supports the growth framework and absorbs fixed costs; a prolonged lull shifts the growth burden to North America and diagnostics and pressures the margin plan.

02

Financial quality

Financial quality: real cash, a thin capital base

GE HealthCare's earnings turn into cash at a respectable but not exceptional rate, and its returns look better than the asset base alone would suggest. Operating cash flow has landed between $1.6 billion and $2.1 billion in each of the past five fiscal years, and free cash flow was positive in all five. Return on equity of about 22% in 2025 sits alongside return on assets near 6%, goodwill larger than total equity, and a current ratio that hovered around 1.0 for four straight years.

Profitability: a high ROE on a thin equity base
Metric (USD bn unless noted)FY2021FY2022FY2023FY2024FY2025Q3 2026¹Assessment
Revenue17.5918.3419.5519.6720.625.51Adequate: low-single-digit growth, 7.2% in the quarter
Gross margin %40.839.140.541.740.0²Not disclosedStrong for a device maker
Operating margin %15.913.712.513.313.4Not disclosedAdequate; 16.6% adjusted EBIT margin in Q3 2026
Net margin %12.810.415.910.110.1²11.1Strong; FY2023 flattered by an item below operating profit
ROE %14.314.737.625.622.1²Not disclosedStrong but leverage-dependent
ROA %8.97.110.36.15.9²Not disclosedAdequate and declining
Liabilities/assets %35.865.277.573.871.3Not disclosedDemanding; reflects the spin-off capital structure
Current ratio1.041.161.051.04Not disclosedNot disclosedThin
Quick ratioNot disclosed0.860.830.83Not disclosedNot disclosedMiddling
Asset turnover x0.700.680.650.600.59²Not disclosedDeclining as the asset base grows
Inventory turnover x5.885.185.655.88Not disclosedNot disclosedTypical for manufacturing
Receivables turnover x5.454.594.744.57Not disclosedNot disclosedAbout 80 days, stable since FY2022
Operating cash flow1.612.112.101.951.990.91Consistent
Free cash flow1.361.801.711.551.510.79Positive every year
Operating cash flow / net income x0.721.100.680.980.961.47Broadly aligned
Free cash flow / net income x0.600.940.550.780.731.29Below 0.8 in three of five years

¹ Three months ended September 30, 2026; a single quarter is not comparable with the full-year columns. ² Calculated from reported revenue, gross profit, net income and equity figures.

Revenue reached $20.62 billion in FY2025, up 4.8%, with gross margin near 40%, a solid level for this industry. Net margin of 10.1% was flat with FY2024 and well below the 15.9% booked in FY2023, when net income of $3.10 billion exceeded EBIT of $2.44 billion. Profit above operating profit points to something below the line, so that year's 37.6% ROE is not a repeatable operating return. The better comparison is FY2024 and FY2025, when ROE stayed between 22% and 26% while ROA fell from 8.9% in FY2021 to 5.9% and asset turnover slipped from 0.70x to 0.59x. Equity is roughly 28% of assets, and goodwill of $13.5 billion at the end of FY2025 exceeds that equity, so leverage and a small book value explain much of the ROE. Margins are improving in 2026: net margin reached 11.1% in the third quarter against 8.7% a year earlier, and adjusted EBIT margin rose to 16.6% from 14.8% on volume, price and cost productivity.

Cash flow: steady totals, late arrivals

Free cash flow ranged from $1.36 billion in 2021 to $1.80 billion in 2022 and settled at $1.51 billion in 2025. As a share of net income it ran between 0.55 and 0.94 over the five years, below 0.8 in three of them, while operating cash flow tracked net income more closely at 0.68 to 1.10. The wedge is capex of roughly $450 million a year, near 2% of revenue. That is light for a manufacturer and keeps free cash flow meaningful, but it leaves open whether the installed imaging base is being replaced at a pace that protects future service revenue.

Timing explains most of the gap against earnings. The fourth quarter of 2025 alone produced $1.05 billion of that year's $1.99 billion of operating cash flow, and the second quarter of 2026 ran at negative $0.52 billion. Receivable days sit near 80, stable since 2022 but above the roughly 67 days implied for 2021, which fits hospital customers on long equipment cycles. The third quarter of 2026 broke the pattern with $907 million of operating cash flow and $793 million of free cash flow, though both figures include a $55 million tariff refund, and the company raised 2026 free cash flow guidance to more than $1.6 billion.

Balance sheet: goodwill above equity and seasonal short-term debt
Quarter (three months)RevenueNet incomeNet margin %Total assetsTotal liabilitiesGoodwillOperating cash flowFree cash flowShort-term debtAssessmentTrend
Q1 20254.780.5611.733.5924.1713.370.250.102.12AdequateStable
Q2 20255.010.499.835.5025.5513.420.090.012.26AdequateStable
Q3 20255.140.458.836.1325.9113.440.590.482.14AdequateSoftening
Q4 20254.670.183.936.9126.3113.491.050.920.51WeakCash-led
Q1 20265.130.397.637.1226.2315.060.290.110.14AdequateImproving
Q2 20265.290.5710.837.2526.2615.09-0.52-0.620.00AdequateCash burn
Q3 20265.510.61511.1Not disclosedNot disclosedNot disclosed0.9070.793Not disclosedStrongImproving

All flows and balances in USD bn; net margins calculated where the company did not state them. Net PP&E is not broken out quarterly; the last disclosed figure was $2.31 billion at the end of 2022.

Debt was $10.0 billion against $2.9 billion of cash on September 30, 2026, with $3.5 billion of undrawn revolvers behind it. Net debt of about $7.1 billion is close to 1.9 times 2025 EBITDA of $3.79 billion, and interest expense of $450 million is covered roughly seven times by operating profit. For a business with 40% gross margins, that is comfortable rather than stretched.

The maturity mix needs watching. Short-term debt was $2.26 billion in mid-2025, $0.51 billion at the 2025 year-end and zero by June 2026, while current liabilities of $8.3 billion sit against $2.1 billion of cash. The company leans on short-dated funding through the year and clears it after fourth-quarter collections, so a credit-market squeeze in a first half would arrive at peak seasonal borrowing. Acquisitions add fixed claims: investing outflow was $2.5 billion in the first quarter of 2026, goodwill rose from $13.49 billion to $15.09 billion by June, and a further $945 million in cash is committed to SOFIE Biosciences, expected to close in the first half of 2027.

What would change the read

Three checks matter most. Whether goodwill keeps rising while ROA falls, since $15.09 billion of goodwill against $10.97 billion of equity means an impairment would hit book value and reported returns together. Whether the mid-year short-term debt peak grows or the year-end paydown slips, which would show funding strain before it reaches the income statement. And whether the 2026 cash improvement holds without one-off help, given that a tariff refund flattered the third quarter. The $23.7 billion backlog and 1.03 times book-to-bill reported for that quarter are the operating evidence that equipment demand keeps converting into collections. If free cash flow settles above $1.6 billion for a second year while conversion to net income holds near 1.0, the earnings-quality case strengthens. If conversion falls back below 0.7 and goodwill climbs again, the returns depend more on the balance sheet than on the business.

Questions worth following

  • Can GE HealthCare's free cash flow keep pace with its margin expansion?

    Margin gains only count if they reach cash. Free cash flow has stayed between $1.4 billion and $1.8 billion for five years while net income moved with items below the operating line, so the 2026 target depends on collections and working capital, not reported profitability alone.

  • Can GE HealthCare absorb the SOFIE purchase without stretching leverage?

    Debt was $10.0 billion against $2.9 billion of cash in September 2026, with roughly $3.8 billion of EBITDA. The $945 million SOFIE acquisition and any further deals test whether cash generation can fund growth while leverage stays near current levels.

  • Will GE HealthCare's adjusted margins converge with GAAP results?

    Guidance rests on adjusted EBIT margin and adjusted EPS, which exclude items that still run through GAAP profit. If the gap between the two measures widens, headline earnings growth overstates the improvement in the underlying business.

Generated by DeepVal AI. Data and models may contain errors or be outdated. For research only; not personalized investment advice.

Go beyond the preview

Continue reading the full report

  1. Key risksWhat could break the investment case
  2. Valuation and margin of safetyWhat the current price assumes, and how much room for error it leaves
  3. SummaryOur overall judgement and what to watch next

Free to sign up · 20 research points · unlocking this report uses 10

20 points cover 2 full reports. No card needed.

Research reflects its generation date. Preview the first two modules.

More on GE HealthCare Technologies Inc.